MENU
+Compare
INTS
Stock ticker: NASDAQ
AS OF
May 9 closing price
Price
$0.54
Change
-$0.03 (-5.26%)
Capitalization
8.23M

INTS Intensity Therapeutics Forecast, Technical & Fundamental Analysis

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers... Show more

INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for INTS with price predictions
May 09, 2025

Momentum Indicator for INTS turns negative, indicating new downward trend

INTS saw its Momentum Indicator move below the 0 level on April 23, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator turned negative. In of the 39 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for INTS turned negative on April 24, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 15 similar instances when the indicator turned negative. In of the 15 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for INTS entered a downward trend on May 07, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

INTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.819) is normal, around the industry mean (14.703). P/E Ratio (0.000) is within average values for comparable stocks, (63.724). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.989). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (253.495).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. INTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

INTS is expected to report earnings to fall 84.62% to -18 cents per share on May 12

Intensity Therapeutics INTS Stock Earnings Reports
Q1'25
Est.
$-0.18
Q4'24
Missed
by $0.95
Q3'24
Beat
by $0.06
Q2'24
Missed
by $0.04
Q4'23
Missed
by $0.05
The last earnings report on March 13 showed earnings per share of -116 cents, missing the estimate of -21 cents. With 169.12K shares outstanding, the current market capitalization sits at 8.23M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1 Enterprise Drive
Phone
+1 203 221-7381
Employees
17
Web
https://www.intensitytherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA298.2613.44
+4.72%
Tesla
GME27.540.76
+2.84%
GameStop Corp
BTC.X104696.3300001725.468800
+1.68%
Bitcoin cryptocurrency
AAPL198.531.04
+0.53%
Apple
SPY564.34-0.72
-0.13%
SPDR® S&P 500® ETF

INTS and Stocks

Correlation & Price change

A.I.dvisor tells us that INTS and GBIO have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INTS and GBIO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INTS
1D Price
Change %
INTS100%
-5.11%
GBIO - INTS
29%
Poorly correlated
+0.06%
MRKR - INTS
29%
Poorly correlated
-9.38%
ACAD - INTS
28%
Poorly correlated
+3.01%
GPCR - INTS
27%
Poorly correlated
-4.66%
CCCC - INTS
27%
Poorly correlated
-4.55%
More